Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated Extensive-Stage.

Published byΦορτουνάτος Παππάς Modified over 5 years ago

Similar presentations

Presentation on theme: "A Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated Extensive-Stage."— Presentation transcript:

1 A Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated Extensive-Stage Small Cell Lung Cancer  Jingwei Jiang, MM, Xiaohua Liang, MD, Xinli Zhou, MD, Lizhen Huang, MS, Ruofan Huang, MD, Zhaohui Chu, MM, Qiong Zhan, MM  Journal of Thoracic Oncology  Volume 5, Issue 6, Pages (June 2010) DOI: /JTO.0b013e3181d95c87 Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Flow of identifying the trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d95c87) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 The meta-analysis showed that irinotecan/platinum (IP) regimens could acquire more overall response than etoposide/platinum (EP) regimens in patients with previously untreated extensive-stage small cell lung cancer (p = 0.043), but the subgroup meta-analysis and sensitivity analysis after the trial using carboplatin was excluded failed to show an advantage in IP regimens (p = 0.065). CBP, irinotecan/carboplatin compared with etoposide/carboplatin subgroup; DDP, irinotecan/cisplatin compared with etoposide/cisplatin subgroup. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d95c87) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 The pooled hazard ratio showed that irinotecan/platinum (IP) could prolong overall survival in patients with previously untreated extensive-stage small cell lung cancer (p = 0.044), but the subgroup meta-analysis and sensitivity analysis after the trial using carboplatin was excluded failed to show an advantage in IP regimens (p = 0.163). CBP, irinotecan/carboplatin compared with etoposide/carboplatin subgroup; DDP, irinotecan/cisplatin compared with etoposide/cisplatin subgroup. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d95c87) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 The pooled hazard ratio for progression-free survival failed to display a difference between irinotecan/platinum and etoposide/platinum regimens in patients with previously untreated extensive-stage small cell lung cancer (p = 0.139). CBP, irinotecan/carboplatin compared with etoposide/carboplatin subgroup; DDP, irinotecan/cisplatin compared with etoposide/cisplatin subgroup. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d95c87) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 The pooled odds ratios for hematological toxicities showed irinotecan/platinum regimens led to less grade 3 to 4 anemia, neutropenia, and thrombocytopenia than etoposide/platinum regimens (p = 0.000, 0.000, and 0.000, respectively). Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d95c87) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

7 FIGURE 6 The pooled odds ratios for nonhematological toxicities showed irinotecan/platinum regimens led to more grade 3 to 4 vomiting and diarrhea than etoposide/platinum regimens, and treatment related deaths were comparable between two groups (p = 0.044, 0.000, and 0.301, respectively). Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d95c87) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "A Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated Extensive-Stage."

Similar presentations

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.
Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network 

Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network 
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer  Sarah Burdett, MSc,

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer  Sarah Burdett, MSc,
Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,
Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study  Thomas.

Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study  Thomas.
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network 

Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell.

A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell.
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

Similar presentations

Ads by Google